^
Association details:
| Biomarker: | KMT2A rearrangement + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | revumenib (SNDX-5613) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
376 Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
Published date:
11/03/2022
Excerpt:
68 patients were treated on Arm A and B, 60 with r/r KMT2Ar or mNPM1 leukemia….The overall response rate (CR+CRh+CRp+CRi/MLFS [ORR]) in the efficacy population (KMT2Ar and mNPM1) was 53% (32/60); the rate of CR+CRh+CRp was 38% (23/60) with a CR/CRh rate of 30% (18/60 [95% CI: 18.8, 43.2])....In SNDX-5613 patients proceeding to transplant, durable remissions occurred across a range of heavily pre-treated patients. In addition to patients achieving CR/CRh, two patients with CRp also had ongoing remissions post-transplant.
DOI:
https://doi.org/10.1182/blood-2022-164600
Trial ID:
